Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects

BioFactors

Volumn 35, Issue 4, 2009, Pages 364-372

  Gerspach, Jeannette ^a   Pfizenmaier, Klaus ^a   Wajant, Harald ^b  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

TNF fusion protein; TNF prodrug

Indexed keywords

AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; CYSTEINYLASPARAGINYLGLYCYLARGINYLCYSTEINYLGLYCINE; DOXORUBICIN; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; FAS LIGAND; GEMCITABINE; HYBRID PROTEIN; IMMUNOGLOBULIN G1; MELANOMA ANTIGEN; MELPHALAN; PACLITAXEL; PRODRUG; SEPRASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY L19; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA, CNGRC FUSION PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA, CNGRC FUSION PROTEIN, MOUSE; TUMOR NECROSIS FACTOR-ALPHA, CNGRC FUSION PROTEIN, HUMAN; TUMOR NECROSIS FACTOR-ALPHA, CNGRC FUSION PROTEIN, MOUSE;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; LIMB PERFUSION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; ANIMAL; NEOPLASM; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; FAS LIGAND PROTEIN; GENETIC ENGINEERING; HUMANS; NEOPLASMS; PRODRUGS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 70449707487     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.50     Document Type: Review

References (79)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
2. Bodmer, J. L., Schneider, P., and Tschopp, J. (2002) The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19-26.
3. Lavrik, I., Golks, A., and Krammer, P. H. (2005) Death receptor signaling. J. Cell Sci. 118, 265-267.
4. Hehlgans, T. and Pfeffer, K. (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115, 1-20.
5. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., and Scheurich, P. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802.
6. Grell, M., Wajant, H., Zimmermann, G., and Scheurich, P. (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA 95, 570-575.
7. Mueller, H. (1998) Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol. Life Sci. 54, 1291-1298.
8. Lejeune, F. J. and Ruegg, C. (2006) Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull. Cancer 93, E90-E100.
9. ten Hagen, T. L., Seynhaeve, A. L., and Eggermont, A. M. (2008) Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol. Rev. 222, 299-315.
10. Gerspach, J., Wajant, H., and Pfizenmaier, K. (2009) Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl. Cell Differ. DOI 10.1007/400-2008-22.
11. Registry of Federally and Privately Supported Clinical Trials Conducted in the United States and Around the World. Available at: http://clinicaltrials. gov. accessed March 2009.
12. Homepage of the Biopharmaceutical Company. GenVec, Gaithersburg, MD. Available at: http://www.genvec.com. accessed March 2009.
13. The Public Face of the Federal E-Government eRulemaking Program. Available at: http://www.regulations.gov. Document ID: FDA-2008-N-0416-0014.2. accessed March 2009.
14. Farma, J. M., Puhlmann, M., Soriano, P. A., Cox, D., Paciotti, G. F., Tamarkin, L., and Alexander, H. R. (2007) Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int. J. Cancer 120, 2474-2480.
15. Balkwill, F. (2006) TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409-416.
16. Wajant, H. (2009) The role of TNF in cancer, results. Probl. Cell Differ. DOI 10.1007/400-2008-26.
17. Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., and Allison, A. C. (1992) Dual role of tumor necrosis factor-a in angiogenesis. Am. J. Pathol. 140, 539-544.
18. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and I. Urushizaki (1988) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 48, 2179-2183.
19. Stoelcker, B., Ruhland, B., Hehlgans, T., Bluethmann, H., Luther, T., and Mannel, D. N. (2000) Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol. 156, 1171-1176.
20. Hoving, S., Seynhaeve, A. L., van Tiel, S. T., Aaan, D. W., de Bruijn, E. A., Eggermont, A. M., and ten Hagen, T. L. (2006) Early destruction of tumor vasculature in tumor necrosis factor-α-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 17, 949-959.
21. Mauceri, H. J., Beckett, M., Liang, A. H., Sutton, H. G., Pitroda, S., Galka, E., Efimova, E., Darga, T., Khodarev, N. N., King, C. R., Posner, M. C., Hellman, S., Kufe, D. W., and Weichselbaum, R. R. (2008) Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 16, 373-381.
22. Nawroth, P., Handley, D., Matsueda, G., De Waal, R., Gerlach, H., Blohm, D. D.Stern (1988) Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168, 637-647.
23. Shimomura, K., Manda, T., Mukumoto, S., Kobayashi, K., Nakano, K., and Mori, J. (1988) Recombinant human tumor necrosis factor-a: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer 41, 243-247.
24. Bierhaus, A., Zhang, Y., Deng, Y., Mackman, N., Quehenberger, P., Haase, M., Luther, T., Muller, M., Bohrer, H., and Greten, J. (1995) Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J. Biol. Chem. 270, 26419-26432.
25. Zhang, Y., Deng, Y., Wendt, T., Liliensiek, B., Bierhaus, A., Greten, J., He, W., Chen, B., Hach-Wunderle, V., Waldherr, R., Ziegler, R., Mannel, D., Stern, D. M., and Nawroth, P. P. (1996) Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma. J. Clin. Invest 97, 2213-2224.
26. Renard, N., Nooijen, P. T., Schalkwijk, L., De Waal, R. M., Eggermont, A. M., Lienard, D., Kroon, B. B., Lejeune, F. J., Ruiter, D. J. (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J. Pathol. 176, 279-287.
27. Menon, C., Ghartey, A., Canter, R., Feldman, M., Fraker, D. L. (2006) Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann. Surg. 244, 781-791.
28. Menon, C., Bauer, T. W., Kelley, S. T., Raz, D. J., Bleier, J. I., Patel, K., Steele, K., Prabakaran, I., Shifrin, A., Buerk, D. G., Sehgal, C. M., and Fraker, D. L. (2008) Tumoricidal activity of high-dose tumor necrosis factor- alpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. Int. J. Cancer 123, 464-475.
29. Calzascia, T., Pellegrini, M., Hall, H., Sabbagh, L., Ono, N., Elford, A. R., Mak, T. W., and Ohashi, P. S. (2007) TNF-α is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 117, 3833-3845.
30. Mocellin, S., Pilati, P., and Nitti, D. (2007) Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr. Pharm. Des. 13, 537-551.
31. Curnis, F., Sacchi, A., Gasparri, A., Longhi, R., Bachi, A., Doglioni, C., Bordignon, C., Traversari, C., Rizzardi, G. P., and Corti, A. (2008) Isoaspartate- glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res. 68, 7073-7082.
32. Curnis, F., Gasparri, A., Sacchi, A., Longhi, R., and Corti, A. (2004) Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 64, 565-571.
33. Wang, H., Chen, K., Cai, W., Li, Z., He, L., Kashefi, A., and Chen, X. (2008) Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol. Cancer Ther. 7, 1044-1053.
34. Wajant, H., Gerspach, J., and Pfizenmaier, K. (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 16, 55-76.
35. Zhao, X., Mohaupt, M., Jiang, J., Liu, S., Li, B., and Qin, Z. (2007) Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res. 67, 4443-4450.
36. Guillem, E. B. and Sampsel, J. W. (2006) Antitumor-associated antigens IgGs: dual positive and negative potential effects for cancer therapy. Adv. Exp. Med. Biol. 587, 341-374.
37. Kim, E. Y. and The, H. S. (2001) TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol. 167, 6812-6820.
38. Kim, E. Y. and The, H. S. (2004) Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J. Immunol. 173, 4500-4509.
39. Kim, E. Y., Priatel, J. J., Teh, S. J., and The, H. S. (2006) TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J. Immunol. 176, 1026-1035.
40. Aspalter, R. M., Eibl, M. M., and Wolf, H. M. (2003) Regulation of TCRmediated T cell activation by TNF-RII. J. Leukoc. Biol. 74, 572-582.
41. Aspalter, R. M., Eibl, M. M., and Wolf, H. M. (2007) Defective T-cell activation caused by impairment of the TNF receptor 2 costimulatory pathway in common variable immunodeficiency. J. Allergy Clin. Immunol. 120, 1193-1200.
42. Chandrasekharan, U. M., Siemionow, M., Unsal, M., Yang, L., Poptic, E., Bohn, J., Ozer, K. Zhou, Z., Howe, P. H., Penn, M., and DiCorleto, P. E. (2007) Tumor necrosis factor alpha (TNF-a) receptor-II is required for TNF-a-induced leukocyte-endothelial interaction in vivo. Blood 109, 1938-1944.
43. Ranges, G. E., Bombara, M. P., Aiyer, R. A., Rice, G. G., Palladino, M. A., Jr. (1989) Tumor necrosis factor-alpha as a proliferative signal for an IL- 2-dependent T cell line: strict species specificity of action. J. Immunol. 142, 1203-1208.
44. Ameloot, P., Fiers, W., De Bleser, P., Ware, C. F., Vandenabeele, P., and Brouckaert, P. (2001) Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants. J. Biol. Chem. 276, 37426-37430.
45. Liu, Y., Cheung, L. H., Marks, J. W., and Rosenblum, M. G. (2004) Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int. J. Cancer 108, 549-557.
46. Liu, Y., Zhang, W., Cheung, L. H., Niu, T., Wu, Q., Li, C., Van Pelt, C. S., and Rosenblum, M. G. (2006) The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia 8, 384-393.
47. Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Biro, A., Siri, A., Orecchia, P., Grassi, J., Neri, D., and Zardi, L. (2003) Selective targeted delivery of TNFa to tumor blood vessels. Blood 102, 4384-4392.
48. Halin, C., Gafner, V., Villani, M. E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 63, 3202-3210.
49. Balza, E., Mortara, L., Sassi, F., Monteghirfo, S., Carnemolla, B., Castellani, P., Neri, D., Accolla, R. S., Zardi, L., and Borsi, L. (2006) Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 12, 2575-2582.
50. van Mierlo, G. J., Scherer, H. U., Hameetman, M., Morgan, M. E., Flierman, R., Huizinga, T. W., and Toes, R. E. (2008) Cutting edge: TNFRshedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J. Immunol. 180, 2747-2751.
51. Mortara, L., Balza, E., Sassi, F., Castellani, P., Carnemolla, B., De Lerma, B. A., Fossati, S., Tosi, G., Accolla, R. S., and Borsi, L. (2007) Therapyinduced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Eur. J. Immunol. 37, 3381-3392.
52. Homepage of the biotechnology company Philogen (Siena, Italy): http://www.philogen.com
53. Bauer, S., Adrian, N., Williamson, B., Panousis, C., Fadle, N., Smerd, J., Fettah, I., Scott, A. M., Pfreundschuh, M., and Renner, C. (2004) Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J. Immunol. 172, 3930-3939.
54. Bauer, S., Adrian, N., Fischer, E., Kleber, S., Stenner, F., Wadle, A., Fadle, N., Zoellner, A., Bernhardt, R., Knuth, A., Old, L. J., and Renner, C. (2006) Structure-activity profiles of Ab-derived TNF fusion proteins. J. Immunol. 177, 2423-2430.
55. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. (2000) Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18, 1185-1190.
56. Curnis, F., Sacchi, A. and Corti, A. (2002) Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110, 475-482.
57. Sacchi, A., Gasparri, A., Gallo-Stampino, C., Toma, S., Curnis, F., and Corti, A. (2006) Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factoralpha. Clin. Cancer Res. 12, 175-182.
58. Sacchi, A., Gasparri, A., Curnis, F., Bellone, M., and Corti, A. (2004) Crucial role for interferon gamma in the synergism between tumor vasculature- targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res. 64, 7150-7155.
59. Crippa, L., Gasparri, A., Sacchi, A., Ferrero, E., Curnis, F., and Corti, V. (2008) Synergistic damage of tumor vessels with ultra low-dose endothelial- monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-a. Cancer Res. 68, 1154-1161.
60. Han, H. K. and Amidon, G. L. (2000) Targeted prodrug design to optimize drug delivery. AAPS. Pharm. Sci. 2, E6, 1-11.
61. Vartak, D. G. and Gemeinhart, R. A. (2007) Matrix metalloproteases: underutilized targets for drug delivery. J. Drug Target 15, 1-20.
62. de Groot, F. M., Damen, E. W., and Scheeren, H. W. (2001) Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumorassociated enzymes, and receptors. Curr. Med. Chem. 8, 1093-1122.
63. Kratz, F., Muller, I. A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem. 3, 20-53.
64. Wuest, T., Gerlach, E., Banerjee, D., Gerspach, J., Moosmayer, D., and Pfizenmaier, K. (2002) TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 21, 4257-4265.
65. Gerspach, J., Muller, D., Munkel, S., Selchow, O., Nemeth, J., Noack, M., Petrul, H., Menrad, A., Wajant, H., and K. Pfizenmaier (2006) Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death. Differ. 13, 273-284.
66. Gerspach, J., Nemeth, J., Munkel, S., Wajant, H., and Pfizenmaier, K. (2006) Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol. Immunother. 55, 1590-1600.
67. Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 87, 7235-7239.
68. Brocks, B., Garin-Chesa, P., Behrle, E., Park, J. E., Rettig, W. J., Pfizenmaier, K., and Moosmayer, D. (2001) Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Mol. Med. 7, 461-469.
69. Egeblad, M. and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
70. Stefanidakis, M. and Koivunen, E. (2006) Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 108, 1441-1450.
71. Pillay, V., Dass, C. R., and Choong, P. F. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25, 33-39.
72. Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., and Sarkar, F. H. (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 34, 122-136.
73. Watermann, I., Gerspach, J., Lehne, M., Seufert, J., Schneider, B., Pfizenmaier, K., and Wajant, H. (2007) Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death. Differ. 14, 765-774.
74. Samel, D., Muller, D., Gerspach, J., Assohou-Luty, C., Sass, G., Tiegs, G., Pfizenmaier, K., and Wajant, H. (2003) Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 278, 32077-32082.
75. Assohou-Luty, C., Gerspach, J., Siegmund, D., Muller, N., Huard, B., Tiegs, G., Pfizenmaier, K., and Wajant, H. (2006) A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J. Mol. Med. 84, 785-797.
76. Bremer, E., ten Cate, B., Samplonius, D. F., de Leij, L. F., and Helfrich, W. (2006) CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107, 2863-2870.
77. Bremer, E., ten Cate, B., Samplonius, D. F., Mueller, N., Wajant, H., Stel, A. J., Chamuleau, M., van de Loosdrecht, A. A., Stieglmaier, J., Fey, G. H., and Helfrich, W. (2008) Superior activity of fusion protein scFvRit: sFasL over cotreatment with rituximab and Fas agonists. Cancer Res. 68, 597-604.
78. Swann, P. G., Tolnay, M., Muthukkumar, S., Shapiro, M. A., Rellahan, B. L., and Clouse, K. A. (2008) Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol. 20, 493-499.
79. De Groot, A. S., McMurry, J., and Moise, L. (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr. Opin. Pharmacol. 8, 620-626.